These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 1295119

  • 1. [Ventricular pro-arrhythmic effects of anti-arrhythmia drugs].
    Jaillon P, Simon T.
    Therapie; 1992; 47(3):187-92. PubMed ID: 1295119
    [Abstract] [Full Text] [Related]

  • 2. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W, Wichter T, Chen X, Hördt M, Willems S, Rotman B, Hindricks G, Kottkamp H, Borggrefe M, Breithardt G.
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [Abstract] [Full Text] [Related]

  • 3. Adverse cardiovascular effects of anti-arrhythmia drugs. Part I: Proarrhythmic effects.
    Libersa C, Caron J, Guedon-Moreau L, Adamantidis M, Nisse C.
    Therapie; 1992; 47(3):193-8. PubMed ID: 1295120
    [Abstract] [Full Text] [Related]

  • 4. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G.
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [Abstract] [Full Text] [Related]

  • 5. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM.
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [Abstract] [Full Text] [Related]

  • 6. [Sotalol and torsades de pointes ventricular tachycardia].
    Petersen HH, Sandøe E.
    Ugeskr Laeger; 1996 May 06; 158(19):2711-6. PubMed ID: 8744073
    [Abstract] [Full Text] [Related]

  • 7. [Drug-induced ventricular tachycardia].
    Fauchier JP, Fauchier L, Babuty D, Breuillac JC, Cosnay P, Rouesnel P.
    Arch Mal Coeur Vaiss; 1993 May 06; 86(5 Suppl):757-67. PubMed ID: 8267504
    [Abstract] [Full Text] [Related]

  • 8. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A, Rudas L, Liszkai G, Fazekas T.
    Orv Hetil; 2003 Feb 02; 144(5):241-7. PubMed ID: 12647553
    [Abstract] [Full Text] [Related]

  • 9. Safety considerations in the pharmacological management of atrial fibrillation.
    Camm AJ.
    Int J Cardiol; 2008 Jul 21; 127(3):299-306. PubMed ID: 18191470
    [Abstract] [Full Text] [Related]

  • 10. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC, Morton BC, Green MS, Tang AS.
    Can J Cardiol; 1997 Apr 21; 13(4):383-6. PubMed ID: 9141970
    [Abstract] [Full Text] [Related]

  • 11. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffolo RR.
    J Pharmacol Exp Ther; 1996 Feb 21; 276(2):637-46. PubMed ID: 8632331
    [Abstract] [Full Text] [Related]

  • 12. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E, Watson T, Lip GY.
    Europace; 2007 Sep 21; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drug-induced torsade de pointes.
    Raehl CL, Patel AK, LeRoy M.
    Clin Pharm; 1985 Sep 21; 4(6):675-90. PubMed ID: 2416504
    [Abstract] [Full Text] [Related]

  • 15. QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone.
    Letsas KP, Filippatos GS, Kounas SP, Efremidis M, Sideris A, Kardaras F.
    Cardiology; 2006 Sep 21; 105(3):146-7. PubMed ID: 16449812
    [No Abstract] [Full Text] [Related]

  • 16. Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity.
    Nogales Asensio JM, Moreno Sánchez N, Doncel Vecino LJ, Villar Mariscal C, López-Mínguez JR, Merchán Herrera A.
    Int J Cardiol; 2007 Jan 08; 114(2):E65-7. PubMed ID: 17056139
    [Abstract] [Full Text] [Related]

  • 17. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling.
    Vos MA, Crijns HJ.
    Anadolu Kardiyol Derg; 2001 Mar 08; 1(1):27-34. PubMed ID: 12122969
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Drugs, QT interval abnormalities and ventricular arrhythmias.
    Thomas SH.
    Adverse Drug React Toxicol Rev; 1994 Mar 08; 13(2):77-102. PubMed ID: 7918900
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.